Golestan University of Medical Sciences Repository

Comparative efficacy of deferiprone, deferoxamine and combination of deferiprone and deferoxamine on serum ferritin value in Beta-Thalassemia patients

Mirbehbahani, N. and Jahazi, A. and Amlashi, H.M. and Behnampour, N. (2015) Comparative efficacy of deferiprone, deferoxamine and combination of deferiprone and deferoxamine on serum ferritin value in Beta-Thalassemia patients. Journal of Krishna Institute of Medical Sciences University, 4 (1). pp. 70-76. ISSN 22314261 (ISSN)

[img]
Preview
PDF - Published Version
Download (76kB) | Preview

Abstract

Background: Iron overload is a predictable and life-threatening complication in patients with thalassemia. Effective and convenient iron chelation remains one of the main targets of clinical management of thalassemia major. The development of a safe and effective chelator has been the goal for many years. Aims and Objective: It was aimed to compare the effect of deferiprone, deferoxamine and combination of deferiprone and deferoxamine on serum ferritin value in beta-thalassemia patients. Material and Methods: This controlled clinical trial was conducted on 46 major beta-thalassemic patients. Fifteen patients in deferiprone group received deferiprone 75mg/kg/day three times a day orally. Nineteen patients in deferoxamine group received deferoxamine 30-50 mg/kg/day subcutaneously for 8-12 hours/day and 5 days per week. Twelve patients in combined therapy group received deferiprone 75 mg/kg/day three times a day orally with deferoxamine 30–50 mg/kg subcutaneously every other day. Serum ferritin value was measured at the beginning and at the end of 6th and 12th months of study. Results: The mean of serum ferritin value in deferiprone group insignificantly increased from 2731± 1398.5 μg/L at the beginning to 2788.5 ± 978.6 μg/L and to 3331.8 ± 1833.9 μg/L at the end of 6th and 12th months of study, respectively. The mean of serum ferritin value in deferoxamine group insignificantly increased from 2883.5 ± 1598.1 μg/L at the beginning to 2935.3 ± 1258.2 μg/L at the end of 6th month of study and decreased to 2773.8 ± 1216.1 μg/L and 12th month of study. The mean of serum ferritin level in combined therapy group significantly decreased from 7498.7 ± 3512.9 μg/L at the beginning to 4839.9 ± 2698.2 μg/L (P < 0.001) and to 4298.2 ± 2288.7 μg/L (P < 0.001) at the end of 6th and 12th months of study, respectively. Conclusion: Combined therapy significantly decreases serum ferritin level. Study suggests deferiprone as a significant addition to support therapy in patients with betathalassemia major on regular transfusion regimens. © 2015 Journal of Krishna Institute of Medical Sciences University.

Item Type: Article
Additional Information: Unmapped bibliographic data: LA - English [Field not mapped to EPrints] J2 - J. Krishna Inst. Med. Sci. Univ. [Field not mapped to EPrints] AD - Department of Hematology, Golestan University of Medical SciencesGorgan, Iran [Field not mapped to EPrints] AD - Department of Midwifery, Islamic Azad University Gorgan BranchGorgan, Iran [Field not mapped to EPrints] AD - Department of Medicine, Golestan University of Medical SciencesGorgan, Iran [Field not mapped to EPrints] DB - Scopus [Field not mapped to EPrints]
Uncontrolled Keywords: Beta-thalassemia, Deferiprone, Deferoxamine, Ferritin
Subjects: مقالات نمایه شده محققین دانشگاه در سایت ,Web of Science ,Scopus
موارد کلی
Divisions: معاونت تحقیقات و فناوری
Depositing User: GOUMS
Date Deposited: 19 Apr 2015 04:07
Last Modified: 24 Dec 2016 08:45
URI: http://eprints.goums.ac.ir/id/eprint/1672

Actions (login required)

View Item View Item